STOCK TITAN

[Form 4] Insmed, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

BWX Technologies, Inc. (NYSE: BWXT) filed a Form 144 indicating that an insider intends to sell up to 3,500 common shares through Charles Schwab & Co. on 06 Aug 2025. The proposed sale has an aggregate market value of roughly $624,922, based on the price at filing, and represents only about 0.004% of the 91.4 million shares outstanding—an immaterial slice of BWXT’s equity base.

The shares were acquired via the lapse of restricted and performance stock awards granted between February 2023 and February 2025. No other sales by the filer have occurred in the past three months, and the notice includes the customary representation that the filer possesses no undisclosed material information. Overall, this appears to be a routine liquidity transaction without obvious strategic implications for the company.

BWX Technologies, Inc. (NYSE: BWXT) ha presentato un Modulo 144 indicando che un insider intende vendere fino a 3.500 azioni ordinarie tramite Charles Schwab & Co. il 6 agosto 2025. La vendita proposta ha un valore di mercato complessivo di circa 624.922 $, basato sul prezzo al momento della presentazione, e rappresenta solo circa lo 0,004% delle 91,4 milioni di azioni in circolazione—una quota irrilevante della base azionaria di BWXT.

Le azioni sono state acquisite tramite la scadenza di premi in azioni vincolate e di performance assegnate tra febbraio 2023 e febbraio 2025. Negli ultimi tre mesi non sono state effettuate altre vendite dal presentatore, e l’avviso include la consueta dichiarazione che il presentatore non possiede informazioni materiali non divulgate. Nel complesso, si tratta di una normale operazione di liquidità senza evidenti implicazioni strategiche per la società.

BWX Technologies, Inc. (NYSE: BWXT) presentó un Formulario 144 indicando que un insider planea vender hasta 3.500 acciones ordinarias a través de Charles Schwab & Co. el 6 de agosto de 2025. La venta propuesta tiene un valor de mercado agregado de aproximadamente 624.922 $, basado en el precio al momento de la presentación, y representa solo alrededor del 0,004% de las 91,4 millones de acciones en circulación—una porción insignificante de la base de capital de BWXT.

Las acciones fueron adquiridas mediante la expiración de premios de acciones restringidas y por desempeño otorgados entre febrero de 2023 y febrero de 2025. No se han realizado otras ventas por parte del presentador en los últimos tres meses, y el aviso incluye la representación habitual de que el presentador no posee información material no divulgada. En general, parece una transacción rutinaria de liquidez sin implicaciones estratégicas evidentes para la empresa.

BWX Technologies, Inc. (NYSE: BWXT)는 내부자가 2025년 8월 6일 Charles Schwab & Co.를 통해 최대 3,500주 보통주를 매도할 계획임을 나타내는 Form 144를 제출했습니다. 제출 시점의 가격을 기준으로 한 제안된 매도 총 시장 가치는 약 624,922달러이며, 이는 발행 주식 총 9,140만 주의 약 0.004%에 불과하여 BWXT의 지분 기반에서 미미한 비중입니다.

해당 주식은 2023년 2월부터 2025년 2월 사이에 부여된 제한 주식 및 성과 주식 보상의 만료를 통해 취득되었습니다. 제출자는 지난 3개월간 다른 매도 기록이 없으며, 제출서에는 제출자가 미공개 중요 정보를 보유하지 않았다는 통상적인 진술이 포함되어 있습니다. 전반적으로, 이는 회사에 명확한 전략적 영향이 없는 일상적인 유동성 거래로 보입니다.

BWX Technologies, Inc. (NYSE : BWXT) a déposé un Formulaire 144 indiquant qu’un initié a l’intention de vendre jusqu’à 3 500 actions ordinaires via Charles Schwab & Co. le 6 août 2025. La vente proposée a une valeur marchande totale d’environ 624 922 $, basée sur le prix au moment du dépôt, et ne représente qu’environ 0,004 % des 91,4 millions d’actions en circulation—une part négligeable de la base de capitaux propres de BWXT.

Les actions ont été acquises par l’expiration de récompenses en actions restreintes et de performance attribuées entre février 2023 et février 2025. Aucun autre vente par le déposant n’a eu lieu au cours des trois derniers mois, et l’avis inclut la déclaration habituelle que le déposant ne détient aucune information matérielle non divulguée. Dans l’ensemble, il semble s’agir d’une opération de liquidité routinière sans implications stratégiques évidentes pour la société.

BWX Technologies, Inc. (NYSE: BWXT) reichte ein Formular 144 ein, in dem ein Insider beabsichtigt, bis zu 3.500 Stammaktien über Charles Schwab & Co. am 6. August 2025 zu verkaufen. Der vorgeschlagene Verkauf hat einen Gesamtmarktwert von etwa 624.922 $, basierend auf dem Kurs zum Zeitpunkt der Einreichung, und stellt nur etwa 0,004 % der 91,4 Millionen ausstehenden Aktien dar – ein unbedeutender Anteil an der Eigenkapitalbasis von BWXT.

Die Aktien wurden durch den Verfall von beschränkten und leistungsbezogenen Aktienzuteilungen erworben, die zwischen Februar 2023 und Februar 2025 gewährt wurden. In den letzten drei Monaten gab es keine weiteren Verkäufe durch den Einreicher, und die Mitteilung enthält die übliche Zusicherung, dass der Einreicher keine nicht offengelegten wesentlichen Informationen besitzt. Insgesamt scheint dies eine routinemäßige Liquiditätstransaktion ohne offensichtliche strategische Auswirkungen für das Unternehmen zu sein.

Positive
  • None.
Negative
  • None.

Insights

TL;DR – Small insider sale; negligible ownership impact, neutral signal.

The 3,500-share sale (~$625 k) equals only 0.004 % of BWXT’s float, well below thresholds that typically influence supply–demand dynamics or indicate insider sentiment shifts. Shares stem from normal vesting of equity compensation, suggesting personal liquidity rather than a change in outlook. No clustering of recent sales or large volume patterns is evident. From a valuation or governance perspective, the filing is not materially impactful.

TL;DR – Routine Form 144 filing, complies with disclosure rules, low governance concern.

The filer discloses all required details—broker, acquisition history, absence of undisclosed adverse information—meeting Rule 144 standards. Lack of sales in the prior three months supports the view that aggregation limits are respected. Because the transaction size is de minimis versus the float and derives from equity-based compensation, it raises no red flags about control changes or information asymmetry.

BWX Technologies, Inc. (NYSE: BWXT) ha presentato un Modulo 144 indicando che un insider intende vendere fino a 3.500 azioni ordinarie tramite Charles Schwab & Co. il 6 agosto 2025. La vendita proposta ha un valore di mercato complessivo di circa 624.922 $, basato sul prezzo al momento della presentazione, e rappresenta solo circa lo 0,004% delle 91,4 milioni di azioni in circolazione—una quota irrilevante della base azionaria di BWXT.

Le azioni sono state acquisite tramite la scadenza di premi in azioni vincolate e di performance assegnate tra febbraio 2023 e febbraio 2025. Negli ultimi tre mesi non sono state effettuate altre vendite dal presentatore, e l’avviso include la consueta dichiarazione che il presentatore non possiede informazioni materiali non divulgate. Nel complesso, si tratta di una normale operazione di liquidità senza evidenti implicazioni strategiche per la società.

BWX Technologies, Inc. (NYSE: BWXT) presentó un Formulario 144 indicando que un insider planea vender hasta 3.500 acciones ordinarias a través de Charles Schwab & Co. el 6 de agosto de 2025. La venta propuesta tiene un valor de mercado agregado de aproximadamente 624.922 $, basado en el precio al momento de la presentación, y representa solo alrededor del 0,004% de las 91,4 millones de acciones en circulación—una porción insignificante de la base de capital de BWXT.

Las acciones fueron adquiridas mediante la expiración de premios de acciones restringidas y por desempeño otorgados entre febrero de 2023 y febrero de 2025. No se han realizado otras ventas por parte del presentador en los últimos tres meses, y el aviso incluye la representación habitual de que el presentador no posee información material no divulgada. En general, parece una transacción rutinaria de liquidez sin implicaciones estratégicas evidentes para la empresa.

BWX Technologies, Inc. (NYSE: BWXT)는 내부자가 2025년 8월 6일 Charles Schwab & Co.를 통해 최대 3,500주 보통주를 매도할 계획임을 나타내는 Form 144를 제출했습니다. 제출 시점의 가격을 기준으로 한 제안된 매도 총 시장 가치는 약 624,922달러이며, 이는 발행 주식 총 9,140만 주의 약 0.004%에 불과하여 BWXT의 지분 기반에서 미미한 비중입니다.

해당 주식은 2023년 2월부터 2025년 2월 사이에 부여된 제한 주식 및 성과 주식 보상의 만료를 통해 취득되었습니다. 제출자는 지난 3개월간 다른 매도 기록이 없으며, 제출서에는 제출자가 미공개 중요 정보를 보유하지 않았다는 통상적인 진술이 포함되어 있습니다. 전반적으로, 이는 회사에 명확한 전략적 영향이 없는 일상적인 유동성 거래로 보입니다.

BWX Technologies, Inc. (NYSE : BWXT) a déposé un Formulaire 144 indiquant qu’un initié a l’intention de vendre jusqu’à 3 500 actions ordinaires via Charles Schwab & Co. le 6 août 2025. La vente proposée a une valeur marchande totale d’environ 624 922 $, basée sur le prix au moment du dépôt, et ne représente qu’environ 0,004 % des 91,4 millions d’actions en circulation—une part négligeable de la base de capitaux propres de BWXT.

Les actions ont été acquises par l’expiration de récompenses en actions restreintes et de performance attribuées entre février 2023 et février 2025. Aucun autre vente par le déposant n’a eu lieu au cours des trois derniers mois, et l’avis inclut la déclaration habituelle que le déposant ne détient aucune information matérielle non divulguée. Dans l’ensemble, il semble s’agir d’une opération de liquidité routinière sans implications stratégiques évidentes pour la société.

BWX Technologies, Inc. (NYSE: BWXT) reichte ein Formular 144 ein, in dem ein Insider beabsichtigt, bis zu 3.500 Stammaktien über Charles Schwab & Co. am 6. August 2025 zu verkaufen. Der vorgeschlagene Verkauf hat einen Gesamtmarktwert von etwa 624.922 $, basierend auf dem Kurs zum Zeitpunkt der Einreichung, und stellt nur etwa 0,004 % der 91,4 Millionen ausstehenden Aktien dar – ein unbedeutender Anteil an der Eigenkapitalbasis von BWXT.

Die Aktien wurden durch den Verfall von beschränkten und leistungsbezogenen Aktienzuteilungen erworben, die zwischen Februar 2023 und Februar 2025 gewährt wurden. In den letzten drei Monaten gab es keine weiteren Verkäufe durch den Einreicher, und die Mitteilung enthält die übliche Zusicherung, dass der Einreicher keine nicht offengelegten wesentlichen Informationen besitzt. Insgesamt scheint dies eine routinemäßige Liquiditätstransaktion ohne offensichtliche strategische Auswirkungen für das Unternehmen zu sein.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lewis William

(Last) (First) (Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chair and CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/04/2025 M(1) 6,830 A $10.85 240,754 I By the Katie Procter Dynasty Trust
Common Stock 08/04/2025 S(1) 1,693 D $108.8(2) 239,061 I By the Katie Procter Dynasty Trust
Common Stock 08/04/2025 S(1) 3,199 D $109.68(3) 235,862 I By the Katie Procter Dynasty Trust
Common Stock 08/04/2025 S(1) 1,938 D $110.91(4) 233,924 I By the Katie Procter Dynasty Trust
Common Stock 303,911 D
Common Stock 50,500 I By the William Lewis Family Legacy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $10.85 08/04/2025 M(1) 6,830 (5) 05/19/2026 Common Stock 6,830 $0 6,865 I By the Katie Procter Dynasty Trust
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. This is the weighted average sales price representing 1,693 shares sold at prices ranging from $108.24 to $109.23 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
3. This is the weighted average sales price representing 3,199 shares sold at prices ranging from $109.25 to $110.23 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
4. This is the weighted average sales price representing 1,938 shares sold at prices ranging from $110.26 to $111.24 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
5. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
Remarks:
/s/ William Lewis, by Michael A. Smith as Attorney-in-fact 08/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BWXT shares are being proposed for sale?

The Form 144 covers 3,500 common shares.

What is the estimated market value of the planned BWXT stock sale?

The aggregate market value stated is approximately $624,922.

When is the insider planning to sell the BWXT shares?

The approximate sale date disclosed is 08 August 2025.

What portion of BWX Technologies’ total shares does 3,500 shares represent?

It equals about 0.004% of the 91,398,740 shares outstanding.

How were the shares to be sold originally acquired?

All shares came from restricted or performance stock vesting between February 2023 and February 2025.

Have there been any other insider sales in the last three months?

The filing indicates “Nothing to Report” for sales in the past three months.

Which broker will handle the BWXT insider’s sale?

Charles Schwab & Co., Inc. is listed as the executing broker.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

21.20B
187.30M
0.75%
110.41%
5.1%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER